Clinical trial
A Prospective, Multinational Study of Real-life Current Standards of Care in Patients With Relapsed and/or Refractory Multiple Myeloma Who Received at Least 3 Prior Lines of Therapy Including PI, IMID, and CD38 Monoclonal Antibody Treatment
NCT04035226 is registered in ClinicalTrials.gov with Janssen-Cilag Ltd. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Prospective, Multinational Study of Real-life Current Standards of Care in Patients With Relapsed and/or Refractory Multiple Myeloma Who Received at Least 3 Prior Lines of Therapy Including PI, IMID, and CD38 Monoclonal Antibody Treatment
- Lead sponsor
- Janssen-Cilag Ltd.
- Phase
- Observational
- Overall status
- Completed
- Start date
- August 2, 2019
- Completion date
- October 27, 2022
- Enrollment
- 254 (actual)
- Sites
- 75
Conditions
As the registry lists them; a condition with its own page is linked.